European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences.
In the event of a foot-and-mouth (FMD) outbreak in a densely populated livestock area within the European Community, emergency vaccination will most likely be employed. The objective of the present study was to support the European FMD control policy by evaluating the between test variability of the European accepted method for assessing the potency, a major determinant in vaccine choice, of an FMD vaccine batch. The test system suffers from low in vivo repeatability and reproducibility (67.6 and 58.8%, respectively). Consequently, the results of 10 identical, individual vaccine potency tests using an FMD virus O1 Manisa vaccine batch indicate that the obtained potency of a vaccine with an overall 50% protective dose (PD(50)) value of 9.99 may vary from 4.59 to 24.25 PD(50).
Goris
N
N
Veterinary and Agrochemical Research Centre, Virology Department, Section of Epizootic Diseases, Groeselenberg 99, 1180 Brussels, Belgium. negor@var.fgov.be
Merkelbach-Peters
P
P
Diev
V I
VI
Verloo
D
D
Zakharov
V M
VM
Kraft
H-P
HP
De Clercq
K
K
D000818:Animals; D002417:Cattle; D004306:Dose-Response Relationship, Immunologic; D005060:Europe; D029544:Foot-and-Mouth Disease Virus / Q000276:immunology*; D008297:Male; D010602:Pharmacopoeias as Topic; D015203:Reproducibility of Results; D014765:Viral Vaccines / Q000276:immunology*
D014765:Viral Vaccines